# VolitionRx Limited (VNRX) · Edgar & Edgarette company card

> VolitionRx Limited (VNRX) grew revenue 40.0% in FY2025 to $2 million, operating margin -1258% against a -4.3% median for in vitro & in vivo diagnostic substances, equity -496% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 93314 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VNRX) · [JSON](https://www.pops4.com/boards/company/VNRX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 40.0% |
| Revenue growth per year | 109.3% |
| Operating margin | -1258.5% (prior year -2190.9%) |
| Net margin | -1360.6% |
| Operating cash flow | −$20M |
| Capital spending | $89,558 |
| Free cash flow | −$20M |
| Cash | $1M |
| Long-term debt | $7M |
| Total assets | $7M |
| Total equity | −$34M |
| Equity ÷ assets | -496.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -151.15 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -1258.5% in FY2025; revenue is hard to predict: its 80% range is ±72%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $1.7M (FY2025), total debt $6.7M. Experience: revenue up 40.0% on the year, up 109.3% a year over 4 years; operating margin -1258.5%, up from -2190.9%. Soundness: equity -496.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.1M and $6.8M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $955K to $7.7M. A statistical range, not company guidance. Against peers (161 filers, $50M+ revenue, its industry group): operating margin -1258.5% against a -4.3% median; growth 40.0% against 12.6%.

Range logged 2026-09-25, receipt e327b5290f692b7f, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-04-23 ([filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226002472/0001477932-26-002472-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226003241/0001477932-26-003241-index.htm))

## Recent filings

- 8-K · filed 2026-10-27 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226006470/0001477932-26-006470-index.htm)
- 8-K · filed 2026-09-25 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226005804/0001477932-26-005804-index.htm)
- 8-K · filed 2026-09-15 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226005620/0001477932-26-005620-index.htm)
- 8-K · filed 2026-09-14 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226005578/0001477932-26-005578-index.htm)
- 8-K · filed 2026-09-02 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226005359/0001477932-26-005359-index.htm)
- 8-K · filed 2026-09-02 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/93314/000147793226005351/0001477932-26-005351-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000093314.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=93314

## Cite

POPS4, Edgar & Edgarette: VolitionRx Limited (VNRX) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/VNRX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.